Original research articleEffect of dienogest-containing oral contraceptives on lipid metabolism
Introduction
The 40-year history of oral contraceptives (OCs) can be characterized as a perpetual attempt to minimize the well-known health risks of this commonly used method. Since the first reports on venous thromboembolic diseases occurring during the intake of OCs, which have been assumed to be caused primarily by the synthetic estrogen component, the efforts for further development of OCs were focussed on the dose reduction of ethinyl estradiol (EE). The idea of using the natural estradiol instead of EE in OCs failed because of the poor cycle control. Another aspect was the assumption that a progestogen component with androgenic properties may cause deleterious effects with respect to the risk of arterial diseases [1]. Consequently, new progestogens that show only weak or no androgenic actions were developed.
The main problem of developing OCs is that the efficacy and risk profile of a new formulation can only be judged on the basis of epidemiologic data, which, however, are available late, i.e., when millions of women have used the preparation for a sufficient duration of time. As a way out of this dilemma, metabolic surrogate parameters that are regarded to reflect possible risk potentials have been chosen. Therefore, the measurement of, e.g., hemostasis parameters, lipids and lipoproteins, or parameters of carbohydrate metabolism, has become mandatory, even though the interpretation of the results with respect to the health risk is questionable.
In search of new preparations that may fulfill the criteria of low-risk OCs, very low doses of EE or even estradiol as the estrogen component were combined with dienogest (DNG), which is a progestogen with no androgenic but with antiandrogenic properties. In the present study, the effect on lipid metabolism of monophasic combinations of 2 mg DNG with either 30 μg or 20 μg EE or 10 μg EE plus 2 mg estradiol valerate (EV) were compared with that of an OC containing 20 μg EE and 100 μg levonorgestrel (LNG).
Section snippets
Design of the study
One-hundred healthy women between 18 years and 35 years of age with regular menstrual cycles and without contraindication for the use of OCs were included in the study according to the inclusion and exclusion criteria. The women had not used any hormonal preparation for at least four weeks prior to the study and did not use drugs that were known to influence the effects of OCs. A gynecological examination including a Papanicolaou smear and a pregnancy test, as well as the assessment of the
Results
Screening was carried out with 110 participants, among which 100 women were randomized and received medication. Eight participants discontinued prematurely from the study, and from one participant no data were available from the treatment phase. Therefore, 91 women completed the study. The statistical analysis was carried out with the data of all 99 participants who received any treatment and for whom data from the treatment phase were available (full-analysis set).
Treatment with the three
Discussion
Lipid metabolism may be affected by sex steroids in a dose- and time-dependent manner [2], [3], [4]. In general, treatment with potent estrogens increases the plasma concentrations of TG and the components of HDL and decreases those of LDL [5], whereas androgens and progestogens with androgenic activity may counteract the estrogen-dependent effects to a certain extent. Among the progestogens used in OCs, the progesterone derivatives possess no or only weak androgenic and partly antiandrogenic
References (36)
Progestogens and arterial disease—evidence from the Royal College of General Practitioners’ study
Am J Obstet Gynecol
(1982)- et al.
Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives
Am J Obstet Gynecol
(1990) - et al.
The metabolic impact of oral contraceptives
Am J Obstet Gynecol
(1992) - et al.
A randomized crossover comparison of two low-dose contraceptiveseffects on serum lipids and lipoproteins
Am J Obstet Gynecol
(1985) - et al.
Progestins and oral contraceptive-induced lipoprotein changesa prospective study
Contraception
(1986) - et al.
Effects of low-dose oral contraceptives on serum lipids and lipoproteinsdifferential changes in high-density lipoprotein subclasses
Am J Obstet Gynecol
(1983) - et al.
Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism
Contraception
(1998) - et al.
Serum lipid and lipoprotein changes by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel
Contraception
(1985) - et al.
The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins
Am J Obstet Gynecol
(1982) - et al.
Effects of three combined oral contraceptive preparations containing desogestrel plus ethinyl estradiol on lipid metabolism in comparison with two levonorgestrel preparations
Am J Obstet Gynecol
(1990)
Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters
Contraception
A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins
Am J Obstet Gynecol
Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 μg gestodene, on lipid metabolism in an open randomized trial
Contraception
Effects of levonorgestrel, and desogestrel in low-dose oral contraceptive combinations on serum lipids, Apos A-I, and B, and glycosylated proteins
Changes in lipid metabolism during 12 months of treatment with two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel
Contraception
A new low-dose estrogen oral contraceptive combinationeffect on endocrine parameters and lipid status
Contraception
Preliminary reportkinetic studies on the modulation of high density lipoprotein, apolipoprotein, and subfraction metabolism by sex steroids in a postmenopausal woman
Metabolism
Hydrolysis of human plasma high density lipoprotein2-phospholipids and triglycerides by hepatic lipase
Biochem Biophys Res Comm
Cited by (46)
Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills
2013, Best Practice and Research: Clinical Endocrinology and MetabolismCitation Excerpt :The magnitude of such effect is related to the potency of the estrogen11 and the androgenicity (or lack of) of the progestin. OCs containing new progestins that are less androgenic such as dienogest, or nomegestrol acetate combined with natural estrogen are shown to have a more favorable effect on the lipid profile in comparison to LNG containing combinations which are more androgenic.45 Agren et al.46 compared the effects of a combination of nomegestrol acetate and 17β-estradiol (NOMAC/E2) on lipids, and other metabolic factors with an LNG/EE OC.
Estradiol Valerate/Dienogest: A Novel Combined Oral Contraceptive
2012, Clinical TherapeuticsCitation Excerpt :Blood samples were taken on days 21 to 26 during a control cycle and then on days 18 to 21 during treatment cycles 1, 3, and 6. Regarding lipid metabolism, the DNG-containing regimens resulted in changes in lipid metabolism than those containing LNG.50 For example, compared with regimens containing DNG, LNG had lower high-density lipoprotein cholesterol 2 levels (P < 0.05) (without significant changes in high-density lipoprotein cholesterol levels) and higher low-density lipoprotein cholesterol levels (P < 0.05) at cycle 6.
The use of newer progestins for contraception
2010, ContraceptionCitation Excerpt :Nonandrogenic progestins have been shown to be neutral on lipid metabolism [6,50]. DNG-containing COC formulations appear to have a favorable effect on lipid metabolism as compared to LNG-containing formulations wherein the EE dose did not seem to play a major role with respect to the effect on lipids [60]. NOMAc has been shown to have no deleterious effect on blood glucose and lipids [61,62].
A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis
2010, International Journal of Gynecology and ObstetricsCitation Excerpt :The absence of notable effects on lipid, carbohydrate, and liver metabolism is consistent with other investigations of dienogest in endometriosis [12,13,21]. A neutral effect on lipids was also observed for dienogest combined with ethinyl estradiol [22]. This profile may represent a benefit for dienogest compared with other therapies such as danazol, which is associated with increased low density lipoprotein (LDL) cholesterol and, in cases, increased total cholesterol levels [23].
Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate
2009, ContraceptionCitation Excerpt :EE/DNG was well tolerated and appeared milder than EE/CPA in terms of gastrointestinal side effects and total number of adverse events. These are consistent with the good tolerability of EE/DNG (shown over treatment exposure corresponding to approximately 8 million women-years until March 2007) and with its relative metabolic neutrality [18,19]. At the same time, EE/DNG had slightly higher rates of breast pain and bleeding events compared with EE/CPA, although the irregular bleeding was mostly spotting or light bleeding (grouped under the preferred term “metrorrhagia”).